|
|
|
|
|
23.05.25 - 02:54
|
Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc. (“NIC”) (the “Transaction”) previously announced on May 13, 2025. The Transaction moves Algernon into the Alzheimer's Disease (“AD”) diagnostic and treatment market, expanding on the Company's existing neurological research programs, and provides Algernon exclusive master franchise and licensing rights to open AD screening, diagnostic, and treatment centers across Canada and in multiple U.S. markets....
|
|
|
|
|
|
|
|
|
|
|
|
|
07.03.25 - 14:33
|
Netcapital to Host Planned Reg A Offering by Algernon NeuroScience (GlobeNewswire EN)
|
|
|
BOSTON, MA, March 07, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ: NCPL, NCPLW), a digital private capital markets ecosystem, today announced that its subsidiary, Netcapital Securities Inc. (“Netcapital Securities”), a FINRA-registered broker-dealer, has been engaged by Algernon NeuroScience Inc. (“Algernon NeuroScience”) for its planned Regulation A (Reg A) offering. Netcapital Securities plans to provide broker-dealer and administrative services, excluding underwriting and placement agent services, in connection with this offering....
|
|
|
06.03.25 - 13:03
|
Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary Algernon NeuroScience (AGN Neuro), has appointed Netcapital Securities Inc. (“Netcapital Securities”), a FINRA-registered broker-dealer, for its planned Regulation A (Reg A) offering. Netcapital plans to provide broker-dealer and administrative services, excluding underwriting and placement agent services, in connection with this offering....
|
|
|
25.02.25 - 05:45
|
Algernon Yau: 10K Foreign Firms Settle in HK Last Yr, Up 10% YoY (AAStocks)
|
|
|
At the end of 2024, Hong Kong had about 10,000 companies from the outside of Hong Kong, up 10% YoY, the largest number on record, indicating that the outside world's trust in Hong Kong will continue to make Hong Kong a major investment destination, Secretary for Commerce and Economic Development, Algernon Yau, said.Hong Kong......
|
|
|
|
|
05.02.25 - 13:03
|
Algernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare′s USD $170K Equity Investment (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Validcare as the contract research organization (“CRO”) for the Company's upcoming randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 stroke patients in Europe. The study is expected to begin enrolling patients in Q3 of 2025. Validcare is a leading U.S. based full service CRO with experience across a wide range of therapeutic indications....
|
|
|
|
|
|
|
|
|
|
|
02.08.24 - 13:03
|
Algernon Pharmaceuticals Announces Closing of Private Placement (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces the close of its non-brokered private placement, previously announced on July 11, 2024 and updated on July 31, 2024, for gross proceeds of $408,000 (the “Offering”) of units (the “Units”) at an issue price of $0.12 per Unit....
|
|
|
31.07.24 - 13:06
|
Algernon Pharmaceuticals Announces Increase to Private Placement (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, July 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced on July 11, 2024, from gross proceeds of $250,000 to $408,000 (the “Offering”) of units (the “Units”) at an issue price of $0.12 per Unit. Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to acquire one Common Share (a “Warrant Share”) at an exercise price of $0.24 per Warrant Share for a period of 2 years from the date of issuance (the “Expiry Date”), subject to acceleration of the Expiry Date as described below. The Offering is expected to close on August 1, 2024....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
